Earnings release
Page 1
1 3Q26 Results São Paulo, November 03, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 3rd quarter of 202 6 (3Q26). The Company's parent company and consolidated financial statements for the periods ended September 30, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the Internationa l Financial Reporting Standards (IFRS) issued by the Internatio nal Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements , which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year. IFRS 16: Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document. HIGHLIGHTS: › Organic expansion maintains a strong pace 3.770 units in operation with 92 openings and 9 closures in the quarter; 333 LTM gross openings, reiterating the guidance of 330-350 gross openings in 2026; › Sales growth remains strong and above inflation Gross revenue of R$ 13.2 billion, +16.0% growth and a R$ 1.8 billion increment; MSSS growth of +8.4%, a real growth +5.6 pp above the annual CMED adjustment; › Market share gains in every region 19.1% national share, a +1.1 pp increase with gains in every region; › Digital sales combine scale and omnichannel leadership Gross revenue of R$ 3.8 billion, +27.2% growth and retail penetration of 29.4%; › Growth with resilient margins Adjusted EBITDA of R$ 1.0 billion, +14.7% & margin of 7.8% (-0.1 pp); Adjusted net income of R$ 439 MM, +9.2% (including 4Bio) & margin of 3.3% (-0.2 pp); Excluding 4Bio impacts, net income growth of +20.1% & margin expansion of +0.1 pp; › Low leverage with cash generation R$ 160 MM positive free cash flow and R$ 57 MM total cash generation; 0.8x ND/EBITDA, a 0.3x reduction. RADL3 R$ 15.22/share Closing Oct 30, 2026 MARKET CAP R$ 26.7 billion NUMBER OF SHARES 1,752,367,344 All ordinary IR TEAM: Flávio Correia André Stolfi Victor Torres Felipe Correa ir.rdsaude.com.br ri@rdsaude.com.br New consolidated summary (ex-4Bio) In R$ thousands 3Q25 4Q25 1Q26 2Q26 3Q26 # of pharmacies 3,453 3,547 3,614 3,687 3,770 Organic openings 88 97 68 76 92 Closures (6) (3) (1) (3) (9) Headcount (EoP) 69,860 73,388 75,190 75,594 77,428 Pharmacist count (EoP) 13,981 14,377 14,965 15,199 15,478 # of tickets (thousands) 111,543 114,731 111,849 119,305 119,277 # of active customers (MM) 51.0 51.7 52.3 52.8 53.3 Gross revenue 11,347,942 12,186,767 11,979,521 12,777,743 13,163,282 Growth (YoY) +15.5% +22.3% +20.4% +18.3% +16.0% Gross profit 3,257,291 3,508,601 3,392,636 3,696,071 3,795,614 % of gross revenue 28.7% 28.8% 28.3% 28.9% 28.8% Adjusted EBITDA 892,592 924,318 820,786 1,017,348 1,023,739 % of gross revenue 7.9% 7.6% 6.9% 8.0% 7.8% Adj. net income (w/ 4Bio) 401,986 361,654 299,752 432,729 439,124 % of gross revenue 3.5% 3.0% 2.5% 3.4% 3.3% Free cash flow 615,609 (466,520) 284,869 549,989 160,161
Page 2
2 3Q26 RESULTS We ended 3Q26 with a total of 3, 770 pharmacies in operation, opening 92 new units in the quarter and 333 LTM. We reiterate our guidance of 330-350 gross openings for 2026. We closed 9 units in 3Q26 totaling 16 LTM, with only 3 still in the maturation process. This equates to less than 1% of the LTM openings, highlighting the precision of our expansion process. The remaining 13 LTM closures were of mature units with an average of 1 1 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC. At the end of 3Q26, a total of 25. 2% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability. Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 697 cities in every state, +44 vs. the prior year, a unique capillarity in Brazilian retail under direct management. We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 35% of the LTM expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country. Lastly, the IRR of new pharmacies continues sustaining record levels , reflecting greater expansion assertiveness supported by the recent efficiency gains in operations, the omnichannel performance, the emerging GLP‑1 market, among other factors. 74.4% 74.7% 74.8% 75.0% 74.8% 7.7% 7.6% 7.6% 7.6% 7.7% 8.4% 8.4% 8.6% 8.5% 8.7% 9.5% 9.3% 8.9% 8.9% 8.8% 3Q25 4Q25 1Q26 2Q26 3Q26 Mature Year 3 Year 2 Year 1 3Q25 4Q25 1Q26 2Q26 3Q26 LTM Gross openings +88 +97 +68 +76 +92 +333 Closures -6 -3 -1 -3 -9 -16 - Maturing - -1 - - -2 -3 - Mature -6 -2 -1 -3 -7 -13 Net openings +82 +94 +67 +73 +83 +317 3,453 3,547 3,614 3,687 3,770 3Q25 4Q25 1Q26 2Q26 3Q26 Pharmacy count Pharmacy portfolio by age 6% 4% 7% 2% 4% 17% 17% 16% 16% 15% 12% 14% 15% 13% 11% 20% 15% 22% 23% 17% 17% 18% 10% 11% 13% 28% 32% 30% 35% 39% 3Q23 3Q24 3Q25 3Q26 3Q26 North Northeast Midwest Southeast South São Paulo LTM Openings Current portfolio 562 610 653 697 3Q23 3Q24 3Q25 3Q26 Pharmacies by formatNumber of cities with pharmacies Pharmacies by region 41% 17% 21% 19% 37% 44% 67% 63% 68% 48% 15% 16% 16% 13% 15% 3Q23 3Q24 3Q25 3Q26 3Q26 Premium Hybrid Popular LTM Openings Current portfolio STORE DEVELOPMENT
Page 3
3 3Q26 RESULTS Our 3 .8 thousand pharmacies are present in every state in the country and supported directly by an integrated network of 16 distribution centers. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a r esult, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage. Our national market share reached 19.1% in the quarter, a solid gain of +1.1 pp vs. the prior year. In addition, we recorded relevant gains across all regions, underscoring our competitive strength in diverse contexts and markets. Market shares reached 3 3.0% in São Paulo (+1.1 pp), 14.3% in the Southeast (+1.1 pp), 24.8% in the Midwest (+1.9 pp), 11.5% in the South (+0.5 pp), 14.2% in the Northeast (+1.3 pp), and 12.1% in the North (+1.0 pp). The +1.1 pp gain in national market share includes the sequential stabilization of GLP-1 products near a 12% share of retail sales. Excluding GLP-1 items, our total market share gain continued robust, a little below +1 pp, with gains across every region. We continued to advance our digital strategy, further strengthening our relationship with the customer. In the last 12 months, we recorded over 1 billion visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 30% more than the average loyal customer. We recorded R$ 3.8 billion in digital channel gross revenue in 3Q26, a growth of + 27% vs. the prior year. The share of these channels was 29.4% of retail sales, an increase of +2.7 pp. Geographic presence Retail Market Share Quarterly share, customer prices, sell-out + sell-in Source: IQVIA. Southeast excludes SP. Total: 3,770 pharmacies Raia: 1,553 Drogasil: 2,217 DCs: 16 PE: 122 SC: 121 DF: 129 GO: 163 PR: 217 RS: 140 MG: 269 MT: 61 SP: 1,485 MS: 70 BA: 147 ES: 82 RJ: 295 AL: 28 SE: 32 PB: 31 RN: 34 CE: 116 PI: 24 MA: 45 TO: 29 PA: 63 RO: 20 AM: 31 AC: 6 RR: 5 AP: 5 18.0% 31.9% 13.2% 22.9% 11.0% 12.9% 11.1% 19.1% 33.0% 14.3% 24.8% 11.5% 14.2% 12.1% Brazil SP Southeast Midwest South Northeast North 3Q25 3Q26 Digital sales and penetration R$ millions, % of retail gross revenue Delivery mixDigital channel mix % of quarterly digital sales % of quarterly digital sales Revenue of digital channels App participation in sales Retail penetration 80 NPS App rating R$ 14.9 B LTM digital sales 83 NPS Delivery rating >1 billion visits Via apps and website LTM 3,018 3,554 3,597 3,938 3,838 81% 82% 83% 83% 83% 26.7% 29.3% 30.2% 31.0% 29.4% 3Q25 4Q25 1Q26 2Q26 3Q26 +27% vs. 3Q25 Click & Collect 66% Up to 60 min 24% >60 min 4% 3rd party 5% App 83% Site 9% Others 3% 3rd party 5% 95% proprietary channels 96% delivered/collected in up to 60min DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT
Page 4
4 3Q26 RESULTS The share of digital channels within sales recorded a sequential decrease of -1.6 pp, entirely driven by the new pricing policy that now offers the sam e GLP-1 discounts in -store, previously exclusive to digital purchases . As a result, the participation of physical channels in this product category increased from 25% in 2Q26 to 40% in October 2026, once again showcasing the importance of the physical pharmacy presence in the customer’s health journey. Tthe remaining product categories continued gaining digital penetration. Among our digital channels, we highlight the intense use of our apps, in which our customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through apps increased +30% vs. the prior year, with a dominant 83% share of digital sales in the quarter. This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It enhances the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius and enables 96% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency. The customer omnichannel experience is strengthened by Stix, our loyalty ecosystem that joins over 9,000 points of sale from the brands Drogasil, Raia, Pão de Açúcar, Extra, Shell and Petlove, in addition to the financial partners Itaú and Livelo. In July 2026, RD Saúde acquired from GPA the remaining 67% of the capital of Stix, taking leadership of the coalition that benefitted 15.6 million active customers, a 26% increase vs. the prior year, of which 6.8 million interacted with 2 or more of the partners. Lastly, we continued to strengthen the role of our pharmacies in the customer’s integral health journey, positioning our locations as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.2 thousand units with Mais Saúde hubs and their expanded services portfolio, in addition to 4 62 units enabled for vaccination. In 3Q26, more than 2.2 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average of 91. We ended 3Q26 with R$ 13,163 million in gross revenue, a 16.0% growth vs. the prior year and a relevant increment of R$ 1.8 billion, in a quarter with a negative calendar effect of 0.3 pp. This pace of growth is in-line with expectations given the stabilization since 4Q25 of GLP -1 items within the products mix. Furthermore, t he incorporation of Stix in 3Q26 contributed +0.4 pp to the quarter’s consolidated growth. We sustained a robust growth across all categories. Branded Rx grew +19.8% in the quarter, still growing at double -digit rates when excluding GLP‑1 products. We highlight that the recent launching of new GLP-1 semaglutide products improves customer accessibility, with the additional unit volume offsetting the relevant reduction in average prices, still sustaining revenue. We note that we still observe limited supply from the industry for these new brands. Meanwhile, the other categories displayed positive performance: Generics grew +11.7%, HPC +13.4%,.and OTC +10.8%, despite a milder winter, above-average rain in the South and Southeast and weaker demand for seasonal items. 11,348 12,187 11,980 12,778 13,163 3Q25 4Q25 1Q26 2Q26 3Q26 44.1% 45.2% 45.5% 45.4% 45.8% 12.6% 12.0% 12.2% 12.4% 12.2% 19.8% 18.5% 18.8% 19.7% 18.9% 23.3% 24.1% 23.4% 22.3% 22.9% 0.2% 0.2% 0.2% 0.2% 0.2% 3Q25 4Q25 1Q26 2Q26 3Q26 +10.8% +11.7% +19.8% 3Q26 vs. 3Q25 * +13.4% * Services Consolidated gross revenue R$ millions Retail sales mix Branded Rx Gen. OTC HPC GROSS REVENUES
Page 5
5 3Q26 RESULTS Finally, we recorded average same‑store sales growth of +10.1% in 3Q26. Among mature stores, which completed the full 3-year ramp-up, we posted an average growth of +8.4%, a pace 5.6 pp above the 2.8% CMED price adjustment authorized in 2026 and 3.8 pp above the LTM CPI. We highlight that, aligned with the market share gains, mature-store performance was strong in all regions, underscoring the elevated competitiveness of our brands within the different market environments. Gross profit totaled R$ 3,795.6 million in 3Q26, equivalent to a gross margin of 2 8.8% with a 0.1 pp expansion vs. the prior year. The incorporation of Stix in 3Q26 contributed with .2 pp. We recorded a 0.2 pp pressure from the NPV adjustments, reflecting the lower Selic interest rate, in addition to pressures from the greater mix of GLP -1 products and of digital channels. These pressures were offset by lower inventory losses and from commercial gains. Selling expenses totaled R$ 2,429.0 million in 3Q26, equivalent to 18.5% of gross revenue, a 0.3 pp pressure vs. the prior year. There we no material effects from the incorporation of Stix. This quarter still includes the 0.5 pp pressure stemming from the 4Q25 investments into our Employee Value Proposition (EVP), in addition to lesser pressures from expenses with security services and last mile deliveries. These were partly offset by dilutions in rentals and payment processing fees, in addition to an important operating leverage derived from the strong mature-store sales growth above inflation. Mature-Store sales growth – RetailConsolidated revenue growth Same-Store sales growth – Retail CMED price adjustment Real growth 3.1% 3.1% 3.1% 2.8% 2.8% 12.4% 19.3% 17.3% 15.5% 13.2% 15.5% 22.3% 20.4% 18.3% 16.0% 3Q25 4Q25 1Q26 2Q26 3Q26 3.1% 3.1% 3.1% 2.8% 2.8% 6.7% 13.2% 11.2% 9.7% 7.3% 9.7% 16.3% 14.3% 12.5% 10.1% 3Q25 4Q25 1Q26 2Q26 3Q26 3.1% 3.1% 3.1% 2.8% 2.8% 4.8% 11.4% 9.7% 8.1% 5.6% 7.8% 14.5% 12.8% 10.9% 8.4% 3Q25 4Q25 1Q26 2Q26 3Q26 GROSS PROFIT SELLING EXPENSES Gross profit R$ millions, % of gross revenue 3,257.3 3,508.6 3,392.6 3,696.1 3,795.6 28.7% 28.8% 28.3% 28.9% 28.8% 3Q25 4Q25 1Q26 2Q26 3Q26 Selling expenses R$ millions, % of gross revenue 2,064.8 2,258.9 2,275.2 2,370.4 2,429.0 18.2% 18.5% 19.0% 18.6% 18.5% 3Q25 4Q25 1Q26 2Q26 3Q26
Page 6
6 3Q26 RESULTS RD Saúde’s corporate structure continued delivering operating leverage. The incorporation of Stix in 3Q26 led to general and administrative expenses totaling R$ 342.9 million, corresponding to 2.6% of gross revenue , stable vs. the prior year. Without Stix, G&A expenses would represent 2.4% of gross revenue, a 0.2 pp dilution. We highlight that the sequential increase in G& A expenses is expected given the provision for the yearly salary adjustment in the state of São Paulo, where our headquarters are located. We recorded an adjusted EBITDA of R$ 1,023.7 million in 3Q26, a 14.7% expansion vs. the prior year. The EBITDA margin was of 7.8% of gross revenue , a 0.1 pp contraction , which in this quarter still includes the effects of the investments into our employee value proposition (EVP). The incorporation of Stix in 3Q26 contributed with 0.1 pp to the quarter’s EBITDA margin. Adjusted depreciation expenses totaled R$ 300.0 million in 3Q26, equivalent to 2.3% of gross revenue, stable vs. the prior year. Adjusted net financial expenses totaled R$ 174.9 million in 3Q26, representing 1.3% of gross revenue, a strong dilution of 0.6 pp vs. the prior year. This dilution includes 0.4 pp stemming from the impacts of a lower average Selic rate upon financial liabilities, resulting in R$ 119.9 million in net financial expenses (0.9% of gross revenue). Additionally, we recorded a financial revenue of R$ 22.7 million from the sale of 4Bio. We also recorded a 0.2 pp dilution from the non-cash NPV adjustment, equivalent to R$ 54.9 million (0.4% of gross revenue). Lastly, we recorded an increase of 31.0% in our adjusted EBT vs. the prior year, totaling R$ 547.6 million in 3Q26. This was equivalent to 4.2% of gross revenue, a 0.5 pp expansion. R$ millions, % of gross revenue Adj. depreciation & amortization Adj. earnings before taxes R$ millions, % of gross revenue Adj. net financial expenses R$ millions, % of gross revenue 264.8 274.7 272.5 277.1 300.0 2.3% 2.3% 2.3% 2.2% 2.3% 3Q25 4Q25 1Q26 2Q26 3Q26 210.9 253.8 215.3 197.3 174.9 1.9% 2.1% 1.8% 1.5% 1.3% 3Q25 4Q25 1Q26 2Q26 3Q26 417.9 398.6 332.9 542.7 547.6 3.7% 3.3% 2.8% 4.2% 4.2% 3Q25 4Q25 1Q26 2Q26 3Q26 GENERAL & ADMINISTRATIVE EXPENSES EBITDA DEPRECIATION, NET FINANCIAL EXPENSES AND EBT General and administrative expenses R$ millions, % of gross revenue 299.9 325.4 296.6 308.3 342.9 2.6% 2.7% 2.5% 2.4% 2.6% 3Q25 4Q25 1Q26 2Q26 3Q26 Adjusted EBITDA R$ millions, % of gross revenue 892.6 924.3 820.8 1,017.3 1,023.7 7.9% 7.6% 6.9% 8.0% 7.8% 3Q25 4Q25 1Q26 2Q26 3Q26
Page 7
7 3Q26 RESULTS We provisioned a total of R$ 108.5 million in adjusted income tax in 3Q26, 0.8% of gross revenue, an increase of 0.2 pp vs. the prior year. The effective tax rate was 19.8% of EBT, a n increase of 2.8 pp driven by the lower proportion of interest on equity provisioned in the quarter. The YTD recurring effective tax rate was of 19.4%. Adjusted consolidated net income was of R$ 439.1 million in 3Q26, with a net margin of 3. 3% of gross revenue . There was no material effect from the incorporation of Stix. When excluding the effects of 4Bio, both its operational profit in 3Q25 (R$ 55.2 million, which included non-recurring tax gains) and the financial revenue in 3Q26 stemming from its sale (R$ 22.7 million), we recorded a net margin of 3.2% in this quarter with a 0.1 pp expansion and an earnings growth of 20.1%. These earnings and margin improvements underscore the resilient aspect of the business, which boasts a solid track record in navigating different economic and political backdrops. We also highlight that these earnings improvements will continue to be complemented by the financial revenue stemming from the sale of 4Bio. Within our EBITDA, we recorded R$ 18.6 million in net non‑recurring expenses in the 3Q26. This includes expenses of R$ 1.5 million in asset write-offs, R$ 0.6 million in social investments & donations, R$ 13.0 million related to tax effects of previous years and R$ 3.4 million in other non-recurring effects. In net income, we recorded a reduction of R$ 6.3 million in income taxes from the non-recurring effects. 346.8 350.2 283.3 424.4 439.1 402.0 361.7 299.8 432.7 439.1 3.5% 3.0% 2.5% 3.4% 3.3% 3Q25 4Q25 1Q26 2Q26 3Q26 * Effective tax rate. Adj. income tax and effective tax rate R$ millions, % of earnings before taxes Adjusted net income (with 4Bio) R$ millions, % of gross revenue Continued operations Discontinued operations 71.1 48.4 49.6 118.3 108.5 17.0% 12.1% 14.9% 21.8% 19.8% 0.6% 0.4% 0.4% 0.9% 0.8% 3Q25 4Q25 1Q26 2Q26 3Q26 * Consolidated net margin Adjusted EBITDA & Net Income Reconciliation (R$ millions) 3Q25 3Q26 Net income 476.1 426.9 Results of discontinued operations (4Bio) (92.1) 0.0 Income tax 90.2 102.2 Equity equivalence (1.0) 1.3 Financial result 210.9 174.9 EBIT (ex-4Bio) 684.0 705.2 Depreciation and amortization 264.8 300.0 EBITDA (ex-4Bio) 948.8 1,005.2 Asset write-offs 1.3 1.5 Social investments and donations 1.6 0.6 Tax effects from previous years (15.6) 13.0 Other non-recurring/non-operating effects (43.6) 3.4 Adjusted EBITDA (ex-4Bio) 892.6 1,023.7 Net income 476.1 426.9 Net non-rec. effects of discont. operations (4Bio) (37.0) - Non-recurring EBITDA effects (56.2) 18.6 Non-rec. effects of cont. op. on income taxes (34%) 19.1 (6.3) Adjusted net income 402.0 439.1 INCOME TAXES AND NET INCOME EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS
Page 8
8 3Q26 RESULTS We recorded a cash cycle improvement of 2.4 days vs. the prior year, totaling 54.2 days in 3Q26. This is already adjusted for discounted receivables, forward payments to suppliers, and also includes the positive effects derived from the end of the ICMS-ST tax regime in the state of São Paulo. We recorded increases of 1.4 days in inventories, due to the lower sales of seasonal items, and of 0.6 days in receivables, more than offset by an increase of 4.4 days in suppliers. We generated R$ 56.8 million in 3Q26. This includes a cash generation in r esources from operations of R$ 771.1 million (5.9% of gross revenue), and an operating cash flow of R$ 578.5 million. We invested R$ 192.7 million in working capital and R$ 418.3 million in CAPEX, comprising of R$ 175.4 million for new pharmacy openings, R$ 90.5 million for maintenance and renovation of existing pharmacies, R$ 86.8 million for technology, R$ 61.9 million for logistics and R$ 3.8 million for other projects. Net financial expenses totaled R$ 119.9 million in 3Q26, partially offset by a tax deduction of R$ 95.1 million related to financial expenses and interest on equity (IoE). Finally, we announced R$ 159.8 million in IoE in 3Q26. Cash Generation and Net Debt Reconciliation (R$ millions) 3Q25 3Q26 Ex-4Bio Adjusted EBIT 627.8 723.7 NPV adjustment (71.1) (59.8) Non-recurring effects 56.2 (18.6) Income tax (34%) (208.4) (219.4) Depreciation 255.2 298.5 Impairment provision (4Bio) - 0.2 Others 125.2 46.5 Resources from operations 784.9 771.1 Cash cycle* 123.5 (394.8) Other assets (liabilities)** 74.4 202.1 Operating cash flow 982.7 578.5 Investments (367.1) (418.3) Free cash flow 615.6 160.2 Investment activities in investees (31.5) (31.7) Interest on equity and dividends (0.1) (0.1) Income tax paid over interest on equity (18.4) (27.6) Net financial expenses*** (145.1) (119.9) Tax benefit (fin. exp., IoE, dividends) 97.2 95.1 Total cash flow (ex-4Bio) 517.7 75.9 Effects from discontinued operations (4Bio) 40.6 (19.0) Total (including 4Bio effects) 558.3 56.8 *Includes adjustments to discounted receivables. **Incl. NPV. ***Excl. NPV. CASH CYCLE CASH FLOW * Adjusted for discounted receivables & advanced payments to suppliers. Cash cycle* COGS days, gross revenue days 101.0 105.7 107.0 103.0 102.4 71.4 74.4 82.0 79.1 75.8 27.0 27.1 28.8 27.8 27.6 56.6 58.4 53.8 51.7 54.2 3Q25 4Q25 1Q26 2Q26 3Q26 Inventories Suppliers Receivables Cash Cycle
Page 9
9 3Q26 RESULTS We ended the 3Q26 with an adjusted net debt of R$ 2,942.7 million, corresponding to a financial leverage ratio of 0.8x the adjusted EBITDA for the last 12 months, a 0.3x leverage reduction vs. the prior year. This reduction is comprised of 0.1x from the regular cash generation of operations and 0.2x from the sale of 4Bio. Our adjusted net debt considers a balance of R$ 621.1 million in discounted receivables, R$ 697.4 million in pending receivables related to the sale of 4Bio and R$ 17.1 million in obligations related to put/call options for remaining equity interests in investee companies. Gross debt totaled R$ 3,505.9 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody’s. Of total indebtedness, 8 8% is long ‑term and 1 2% is short‑term. We ended the quarter with a total cash and equivalents position of R$ 504.0 million. We highlight that, d espite already recording a low leverage of 0.8x, we expect additional cash generation over time from the recovery of ICMS-ST taxes in the state of São Paulo. Our share price increased by 10.0% in 3Q26, while the IBOVESPA index increased by 7.0%. During the period, the average daily trading volume (ADTV) was of R$ 192.2 million. Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,220%, compared to only 238% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 18.5%. Considering the IPO of Raia in December 2010, the cumulative return amounted to 566%, compared to 174% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 13.7%. Net debt ex-4Bio (R$ millions) 3Q25 4Q25 1Q26 2Q26 3Q26 Short-term debt 522.5 508.1 425.5 365.3 417.3 Long-term debt 2,760.1 3,359.6 3,236.1 3,087.4 3,088.6 Total gross debt 3,282.6 3,867.8 3,661.5 3,452.6 3,505.9 (-) Cash and equivalents 339.6 358.6 441.8 536.5 504.0 Net debt 2,943.0 3,509.1 3,219.7 2,916.1 3,001.9 Discounted receivables 514.7 800.3 953.6 808.9 621.1 Advances to suppliers (3.7) - - (25.7) - Sale of 4Bio - Pending receivables - - - (716.4) (697.4) Investment put/call options (estimated) 22.8 15.5 15.9 16.6 17.1 Adjusted net debt 3,476.7 4,324.9 4,189.2 2,999.6 2,942.7 LTM adjusted EBITDA 3,056.3 3,303.1 3,500.7 3,655.0 3,786.2 Adjusted net debt/LTM EBITDA 1.1x 1.3x 1.2x 0.8x 0.8x INDEBTEDNESS TOTAL SHAREHOLDER RETURNS
Page 10
10 3Q26 RESULTS Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde’s Investor Relations website (ir.rdsaude.com.br), the financial statements can be found in the 'Results Spreadsheets' section. 3Q26 Change Income Statement (R$ millions) Pre IFRS 16 IFRS 16 ∆ 3Q26 Gross Revenue 13,163.3 13,163.3 0.0 Gross Profit 3,795.6 3,797.3 1.7 Gross Margin 28.8% 28.8% 0.0 pp Selling Expenses (2,429.0) (2,061.2) 367.7 G&A (342.9) (342.0) 0.9 Total Expenses (2,771.9) (2,403.2) 368.6 as % of Gross Revenue 21.1% 18.3% (2.8 pp) Adjusted EBITDA 1,023.7 1,394.1 370.3 as % of Gross Revenue 7.8% 10.6% 2.8 pp Non-Recurring Expenses / Revenues (18.6) (16.5) 2.0 Depreciation and Amortization (300.0) (561.5) (261.5) Financial Results (174.9) (314.0) (139.1) Income Tax (102.2) (92.6) 9.6 Net income ex-4Bio 426.9 408.3 (18.6) as % of Gross Revenue 3.2% 3.1% (0.1 pp) Net Income 426.9 408.2 (18.6) as % of Gross Revenue 3.2% 3.1% (0.1 pp) 3Q26 Change Balance Sheet (R$ millions) Pre IFRS 16 IFRS 16 ∆ 3Q26 Assets 20,766.0 25,624.7 4,858.6 Current Assets 14,636.7 14,636.7 (0.0) Non-Current Assets 6,129.3 10,988.0 4,858.6 Income Tax and Social Charges deferred 53.3 291.0 237.7 Other Credits 560.8 560.4 (0.5) Investments 0.2 0.0 (0.2) Right of use 0.0 4,621.5 4,621.5 Liabilities and Shareholder's Equity 20,766.0 25,624.7 4,858.6 Current Liabilities 9,445.7 10,479.1 1,033.3 Financial Leases 0.0 1,039.8 1,039.8 Other Accounts Payable 610.2 603.8 (6.4) Non-Current Liabilities 3,307.1 7,594.1 4,287.0 Financial Leases 0.0 4,287.0 4,287.0 Shareholder's Equity 8,013.2 7,551.5 (461.7) Income Reserves 2,489.1 2,075.7 (413.4) Accrued Income 528.2 479.8 (48.3) Equity Adjustments 63.0 63.0 (0.1) IFRS-16
Page 11
11 3Q26 RESULTS OTC – Over the Counter MSSS/SSS – Mature Same-Store Sales/Same-Store Sales Digital sales – Sales through digital channels, such as apps, e-commerce, phone, digital partners, among others LTM – Last Twelve Months DC – Distribution Center NPV – Net Present Value CMED – Inter-ministerial government body responsible for the economic regulation of Brazil’s medicine market EVP – Employee Value Proposition EBITDA – Earnings Before Interest, Taxes, Depreciation and Amortization Adjusted EBITDA – EBITDA excluding non-recurring results November 04, 2026 - 10:00 AM (UTC-3), with simultaneous translation to English. Access link https://www.resultadosrdsaude.com.br/ For more information, please contact our Investor Relations department: ri@rdsaude.com.br 3Q26 Change Cash Flow (R$ millions) Pre IFRS 16 IFRS 16 ∆ 3Q26 Adjusted EBIT 723.7 832.6 108.9 Non-Recurring Effects (18.6) (16.5) 2.0 Income Tax (34%) (219.4) (257.1) (37.7) Depreciation 298.5 561.5 263.0 Rental Expenses 0.0 (370.7) (370.7) Impairment provision (4Bio) 0.2 0.2 0.0 Others 46.5 81.2 34.7 Resources from Operations 771.1 771.4 0.2 Operating Cash Flow 578.5 578.5 0.0 Investments (418.3) (418.3) 0.0 Free Cash Flow 160.2 160.2 0.0 Total cash flow (ex-4Bio) 75.9 75.9 0.0 Total cash flow (with 4Bio) 56.8 56.8 0.0 GLOSSARY RESULTS CONFERENCE CALL
Page 12
12 3Q26 RESULTS Consolidated adj. income statement 3Q25 3Q26 (R$ thousands) Resubmitted Gross revenue 11,347,942 13,163,282 Taxes, deductions and returns (767,440) (1,754,278) Net revenue 10,580,502 11,409,004 Cost of goods sold (7,323,211) (7,613,390) Gross profit 3,257,291 3,795,614 % of gross revenue 28.7% 28.8% Selling expenses (2,064,781) (2,428,957) General and administrative expenses (299,919) (342,917) Operational expenses (2,364,700) (2,771,875) % of gross revenue (20.8%) (21.1%) Adjusted EBITDA 892,592 1,023,739 % of gross revenue 7.9% 7.8% Depreciation and amortization (264,817) (300,007) Adjusted EBIT 627,775 723,732 Financial expenses (340,850) (337,366) Financial revenue 129,924 162,494 Adjusted financial results (210,926) (174,873) Equity equivalence 1,034 (1,253) Adjusted EBT 417,883 547,606 Income tax and social charges (71,071) (108,468) Adjusted net income ex-4Bio 346,812 439,139 % of gross revenue 3.1% 3.3% Discontinued operations (4Bio) 55,174 (15) Adjusted net income 401,986 439,124 % of gross revenue 3.5% 3.3%
Page 13
13 3Q26 RESULTS Consolidated income statement 3Q25 3Q26 (R$ thousands) Resubmitted Gross revenue 11,347,942 13,163,282 Taxes, deductions and returns (767,440) (1,754,278) Net revenue 10,580,502 11,409,004 Cost of goods sold (7,323,211) (7,613,390) Gross profit 3,257,291 3,795,614 Selling expenses (2,064,781) (2,428,957) General and administrative expenses (299,919) (342,917) Other operational expenses, net 56,244 (18,563) Operational expenses (2,308,456) (2,790,438) EBITDA 948,835 1,005,176 Depreciation and amortization (264,817) (300,007) EBIT 684,018 705,169 Financial expenses (340,850) (337,366) Financial revenue 129,924 162,494 Financial results (210,926) (174,873) Equity equivalence 1,034 (1,253) EBT 474,126 529,043 Income tax and social charges (90,194) (102,156) Net income ex-4Bio 383,933 426,887 Results of discontinued operations (4Bio) 92,145 (15) Net income 476,078 426,872
Page 14
14 3Q26 RESULTS Assets (R$ thousands) 3Q25 3Q26 Cash and cash equivalents 339,615 503,986 Financial investments 102,050 123,210 Accounts receivable 2,848,274 3,372,755 Inventories 8,125,437 8,568,312 Taxes receivable 466,246 908,247 Anticipated expenses 115,993 170,426 Judicial deposits 6,825 3,027 Assets of investment for sale (4Bio) 1,504,998 - Other accounts receivable 608,926 986,743 Current assets 14,118,364 14,636,706 Deposit in court 58,853 65,317 Taxes receivable 233,345 270,646 Income tax and social charges deferred 46,164 53,301 Other credits 9,951 560,844 Investments 16,660 186 Property, plant and equipment 2,822,576 3,102,481 Intangible 2,064,727 2,076,551 Non-current assets 5,252,276 6,129,326 TOTAL ASSETS 19,370,640 20,766,031 Liabilities and shareholder equity (R$ thousands) 3Q25 3Q26 Suppliers 5,739,195 6,340,844 Loans and financing 522,497 417,271 Salaries and social charges payable 895,260 1,044,588 Taxes payable 453,140 570,626 Dividends and interest on equity 338,196 437,411 Provision for lawsuits 48,336 24,810 Liabilities of investment for sale (4Bio) 551,325 - Other accounts payable 442,815 610,196 Current liabilities 8,990,764 9,445,746 Loans and financing 2,760,116 3,088,611 Provision for lawsuits 143,283 167,493 Income tax and social charges deferred 2,356 (49) Other accounts payable 64,948 51,024 Non-current liabilities 2,970,703 3,307,078 Common stock 4,000,000 4,750,000 Capital reserves 125,346 172,087 Revaluation reserve 10,991 10,862 Income reserves 2,529,320 2,489,084 Accrued income 666,109 528,151 Equity adjustments 62,969 63,023 Non controller interest 14,437 - Shareholder equity 7,409,172 8,013,207 TOTAL LIABILITIES & SHAREHOLDER EQUITY 19,370,640 20,766,031
Page 15
15 3Q26 RESULTS Cash Flow 3Q25 3Q26 (R$ thousands) Earnings before Income Tax and Social Charges 566,263 529,043 Adjustments Depreciation and Amortization 256,356 298,522 Compensation plan with restricted shares, net (5,761) 12,265 Interest over additional stock option 8,325 569 PP&E and Intangible Assets residual value 7,717 7,556 Provisioned Lawsuits 44,727 28,375 Provisioned Inventory Loss 8,939 (1,777) Provision for Doubtful Accounts 5,500 3,918 Provisioned Store Closures (330) (3,810) Interest Expenses 155,720 124,905 Debt Issuance Costs Amortization 2,326 1,891 Equity Equivalence Result (1,026) 1,235 Provision for realization of recoverable investment - 206 1,048,756 1,002,898 Assets and Liabilities variation Clients and Other Accounts Receivable (387,034) (280,926) Inventories (183,482) (232,639) Other Short Term Assets 18,108 (120,328) Suppliers 465,443 (43,370) Salaries and Social Charges 118,243 119,033 Taxes Payable 6,674 161,244 Other Liabilities (107,088) (34,661) Rents Payable 5,004 (15,613) Cash from Operations 984,624 555,638 Interest Paid (122,531) (73,499) Income Tax and Social Charges Paid (81,744) (43,401) Paid lawsuits (29,694) (23,370) Discontinued operational activities (4Bio) - 2,252 Net Cash from (invested) Operational Activities 750,655 417,620 Investment Activities Cash Flow PP&E and Intangible Acquisitions (378,062) (463,979) PP&E Sale Payments 573 - Restricted Investments (23,772) (6,761) Acquisitions and capital contributions in investments, net - (20,700) Cash from divestments - 41,411 Net Cash from Investment Activities (401,261) (450,029) Financing Activities Cash Flow Payments (440,000) - Interest on Equity and Dividends Paid (75) (105) Net Cash from Funding Activities (440,075) (105) Cash and equivalents in the beggining of the period (with 4Bio) 527,020 536,500 Cash and equivalents net increase (with 4Bio) (90,681) (32,514) Cash and equivalents in the end of the period (with 4Bio) 436,339 503,986